This observation generates two hypotheses as follows: (1) DNG may be less efficacious in patients bearing KRAS-mutated adenomyotic clones, allowing these abnormal cells to persist until surgery; and (2) DNG treatment drives an enrichment of KRAS mutations in adenomyosis. The gene discussed is KRAS; the disease is adenomyosis.